Efficacy and safety of phosphate binders in patients on hemodialysis

Efficacy and safety of phosphate binders in patients on hemodialysis - Phosphate binders in patients on HD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031733

Enrollment

Registered

2018-03-14

Start date

2017-01-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing maintenance hemodialysis

Interventions

Sucroferric oxyhydroxide or ferric citrate hydrate Lanthanum carbonate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) hemodialysis duration >2 years at enrollment, and (2) hyperphosphatemia that was treated with lanthanum carbonate at least 12 weeks before enrollment.

Exclusion criteria

Exclusion criteria: (1) a history of severe heart failure, angina, myocardial infarction, or stroke within the past 6 months; (2) the presence of infectious disease, malignant tumors, or treatment with steroids or immunosuppressants; (3) current hospitalization

Design outcomes

Primary

Measure	Time frame
Changes in serum phosphate levels, hepcidin, and FGF23 levels	—

Secondary

Measure	Time frame
Changes in serum iron, TSAT, ferritin levels, hemoglobin concentration, dose of erythropoiesis stimulating agents, and erythropoietin responsiveness index, and safety.	—

Countries

Japan

Contacts

Public ContactTomoyasu Otsuki

Nihon University School of Medicine Nephrology, Hypertension and Endocrinology

totsuki16@gmail.com03-3972-8311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026